Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01983501
Title A Phase 1b Study of ONT-380 Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Oncothyreon Inc.
Indications

Her2-receptor positive breast cancer

Therapies

Ado-trastuzumab emtansine + Tucatinib

Age Groups: adult | senior
Covered Countries USA | CAN

Facility Status City State Zip Country Details
University of Alabama Birmingham Alabama 35294 United States Details
University of Colorado Cancer Center Aurora Colorado 80045 United States Details
University of Kansas Kansas City Kansas 66160 United States Details
Dana Farber Cancer Institute Boston Massachusetts 02215 United States Details
Providence Cancer Center Portland Oregon 97213 United States Details
Sarah Cannon Research Institute Nashville Tennessee 37203 United States Details
Northwest Medical Specialties Tacoma Washington 98045 United States Details
London Health Sciences Centre London Ontario N6A 5W9 Canada Details
Princess Margaret Cancer Centre Toronto Ontario M5T 2M9 Canada Details
Hospital de la Cite-de-la-Sante Laval Quebec H7M 3L9 Canada Details
Jewish General Hospital Montreal Quebec H3T 1E2 Canada Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field